Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public











Title  Creator  Group name  Publishing year 
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation Frenel et al. EquipeCTCS 2023-06
Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort Bringuier et al. EquipeCTCS 2022-02
Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME) Dano et al. EquipeELC 2021-08
Evolution of overall survival and receipt of new therapies by subtype among 20?446 metastatic breast cancer patients in the 2008-2017 ESME cohort Grinda et al. EquipeCTCS 2021-06
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis Gaillard et al. EquipeELC 2021-10-21
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database Gougis et al. EquipeCTCS Oct 19, 2019
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer Cottu et al. EquipePC Oct 11, 2018
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study Delaloge et al. EquipeCTCS 09/2016


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés